Rheumatology treats musculoskeletal and autoimmune diseases, including arthritis, lupus, gout, and vasculitis.
Send us all your questions or requests, and our expert team will assist you.
The management of Juvenile Idiopathic Arthritis has undergone a revolution in the last two decades, shifting from a strategy of symptom relief to one of disease modification. The therapeutic approach is often conceptualized as a pyramid or a step-up/step-down approach, tailored to disease severity.
When NSAIDs and local steroids are insufficient, or in polyarticular/systemic cases, DMARDs are initiated.
Pharmacology controls the fire, but physical therapy rebuilds the house. Rehabilitation is integral to management. The goals are to relieve pain, preserve joint range of motion, maintain muscle strength, and prevent deformities.
While current treatments are suppressive, the future lies in regeneration and modulation. Research into Mesenchymal Stem Cells (MSCs) is exploring their potential to treat refractory JIA. MSCs are not used here to “grow new cartilage” directly, but rather for their potent immunomodulatory capabilities. They secrete soluble factors that can inhibit T-cell proliferation and promote the generation of Regulatory T cells (Tregs), which are the body’s natural peacemakers. This “resetting” of the immune system could, in theory, offer long-term remission without the need for continuous immunosuppression. Additionally, Platelet-Rich Plasma (PRP) is being investigated for localized cartilage support, delivering growth factors directly to the damaged joint surface to help maintain the chondral matrix.
Surgery is rarely needed today due to improved medical management. However, in cases of severe, irreversible joint destruction or deformity, orthopedic intervention is considered.
Send us all your questions or requests, and our expert team will assist you.
Biologics are a class of advanced medications that are genetically engineered from living cell cultures. Unlike traditional chemical drugs, they are complex proteins designed to target very specific parts of the immune system, such as a single type of inflammatory protein (like TNF or Interleukin), blocking its action to stop inflammation at its source.
Methotrexate was originally developed as a chemotherapy drug for cancer, but in the treatment of arthritis, it is used in vastly lower doses. At these low doses, it acts as an anti-inflammatory and immune-modulating agent, not a cell-killing toxin. The side-effect profile at arthritis doses is very different from that at cancer treatment doses.
Not necessarily. The goal of treatment is to achieve “inactive disease” or remission. Once a child has been in remission for a sustained period (often 6 to 12 months) on medication, doctors will often attempt to slowly taper and eventually discontinue the drugs. Many children achieve drug-free remission, although some may need long-term maintenance.
Physical therapy is essential for preventing permanent disability. Medicine reduces swelling, but physical therapy helps the joint keep moving correctly. It prevents muscles from wasting away, stops joints from freezing in bent positions (contractures), and helps the child maintain normal walking patterns and daily function.
The injection itself involves a needle and can be uncomfortable. However, doctors typically use local anesthetic creams or sprays to numb the skin. For younger children or when injecting multiple joints, conscious sedation or general anesthesia is frequently used so the child has no memory of the procedure and feels no pain.
Your Comparison List (you must select at least 2 packages)
